U.S. Markets closed

Vical Q4 Loss Narrows

Zacks Equity Research

Vical Incorporated (VICL) reported a loss of 3 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate and the year-ago loss of 9 cents per share.

Total revenues in the reported quarter were $3.15 million, up 34.7% from the year-ago quarter and above the Zacks Consensus Estimate of $2 million. Revenues comprise contract and grants revenues and licence and royalty revenues.

Loss per share in 2013 was 36 cents, up 33.3% from 2012, narrower than the Zacks Consensus Estimate loss of 41 cents.

Revenues declined 55.9% to $7.7 million but surpassed the Zacks Consensus Estimate of $6 million. The year-ago figure included a $10 million milestone payment from partner Astellas Pharma, Inc. (ALPMY) related to the development of ASP0113.

The Quarter in Detail

Research and development (R&D) expenses decreased 26.5% to $2.5 million from the year-ago quarter.

General and administrative (G&A) expenses also decreased 37% to $1.7 million from the year-ago quarter.

Vical continues to focus on the development of its pipeline. In Dec 2013, Vical started a phase I/II study of the therapeutic vaccine formulated with Vaxfectin, for herpes simplex virus type 2 that causes genital herpes. The study is evaluating safety, tolerability and efficacy of the vaccine in 156 patients aged 18 to 50 years.

Vical, in collaboration with Astellas, has commenced a phase III study on ASP0113, which will evaluate the survival rate of CMV seropositive patients who have undergone hematopoietic stem cell transplant (:HCT).

Meanwhile, a phase II study on ASP0113 is under progress to evaluate its efficacy in cytomegalovirus (:CMV)-seronegative patients who have received a kidney from a CMV-seropositive donor.

Net cash burn is expected to be $13 million - $16 million in 2014.

Vical carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotechnology sector include Actelion Ltd. (ALIOF) and Biogen Idec Inc. (BIIB). Both these stocks hold a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on ALIOF
Read the Full Research Report on BIIB
Read the Full Research Report on ALPMY
Read the Full Research Report on VICL


Zacks Investment Research